Category Archives: Strategy

Takeda Changes Dexlansoprazole Brand Name From Kapidex to Dexilant

By Oriana Schwindt | Published: March 5, 2010
Takeda’s US subsidiary launched its proton pump inhibitor dexlansoprazole last February under the name Kapidex. No one thought they’d have to find a new name a year later. But shortly after the launch, the company began getting reports of dispensing errors. Some were due to prescription misreading, others to simple, honest mistakes. The two drugs causing [...]
Also posted in Corporate Responsibility, FDA, Marketing, News, Safety | Tagged , , , , , , , , , , | 1 Comment

Merck, Lilly, Pfizer: One for All and All for One

By Oriana Schwindt | Published: February 24, 2010
Just a month after Andrew Witty’s announcement that GSK will make more than 13,500 of its malaria compounds available to all, Pfizer, Merck, and Eli Lilly have thrown their do-gooder hats into the ring as well. Together, the three drug giants will pull together an undisclosed dollar amount in seed funding and create the independent, non-profit [...]
Posted in Strategy | Tagged , , , , , , , | Leave a comment

Help Us Help You

By Pharm Exec | Published: February 12, 2010
Sponsored Blog by: Craig Nestel Business Solutions Manager SAS Global Healthcare and Life Sciences Practice I wasn’t the biggest fan of the movie Jerry McGuire, but it certainly had its share of memorable quotes. Who can forget “mission statement” or “show me the money!” My personal favorite was “help me help you” which brings me to the subject of [...]
Also posted in Guest Blog | Tagged , , , , , , , | Leave a comment

Will Europe Stay Coy on Information to Patients?

By Julian Upton | Published: February 3, 2010
Guest blog by Reflector, Pharm Exec Europe’s Brussels correspondent. American drug firms have been pushing for it for years, and so — in an entirely different direction — has the European Parliament. Patient groups are divided over whether it’s needed. The European Commission (EC) says it’s definitely time for action. But EU member states — and [...]
Posted in Strategy | Leave a comment

A Few Words About Diversification

By Julian Upton | Published: February 1, 2010
Guest blog by Dr Brian White, an analyst at Shore Capital. As a result of the feared impact of the patent expiry cliff, the decimation of branded sales by multi-sourced generics and the obstacles erected, especially by managed care in the US, to slow the uptake of branded pharmaceuticals where a generic in the same class [...]
Also posted in Europe, Global, Guest Blog | Tagged , , , , , , | Leave a comment